Prostate-specific antigen 10–20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy gleason score 6

Glen Denmer R. Santok, Ali Abdel Raheem, Lawrence H.C. Kim, Kidon Chang, Trenton G.H. Lum, Byungha Chung, Youngdeuk Choi, KoonHo Rha

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: This study aimed to identify the predictors of upgrading and degree of upgrading among patients who have initial Gleason score (GS) 6 treated with robot-assisted radical prostatectomy (RARP). Materials and Methods: A retrospective review of the data of 359 men with an initial biopsy GS 6, localized prostate cancer who underwent RARP between July 2005 to June 2010 was performed. They were grouped into group 1 (nonupgrade) and group 2 (up-graded) based on their prostatectomy specimen GS. Logistic regression analysis of studied cases identified significant predictors of upgrading and the degree of upgrading after RARP. Results: The mean age and prostate-specific antigen (PSA) was 63±7.5 years, 8.9±8.77 ng/mL, respectively. Median follow-up was 59 months (interquartile range, 47–70 months). On multivariable analysis, age, PSA, PSA density and ≥2 cores positive were predictors of upgrading with (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.01–1.06; p=0.003; OR, 1.006; 95% CI, 1.01–1.11; p=0.018; OR, 0.65; 95% CI, 0.43–0.98, p=0.04), respectively. On subanalysis, only PSA level of 10–20 ng/mL is associated with upgrading into GS ≥8. They also had lower biochemical recurrence free survival, cancer specific survival, and overall survival (p≤0.001, p=0.003, and p=0.01, respectively). Conclusions: Gleason score 6 patients with PSA (10–20 ng/mL) have an increased risk of upgrading to pathologic GS (≥8), subsequently poorer oncological outcome thus require a stricter follow-up. These patients should be carefully counseled in making an optimal treatment decision.

Original languageEnglish
Pages (from-to)90-97
Number of pages8
JournalInvestigative and clinical urology
Volume58
Issue number2
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Neoplasm Grading
Prostate-Specific Antigen
Prostatectomy
Biopsy
Odds Ratio
Confidence Intervals
Survival
Prostatic Neoplasms
Logistic Models
Regression Analysis
Recurrence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Santok, Glen Denmer R. ; Raheem, Ali Abdel ; Kim, Lawrence H.C. ; Chang, Kidon ; Lum, Trenton G.H. ; Chung, Byungha ; Choi, Youngdeuk ; Rha, KoonHo. / Prostate-specific antigen 10–20 ng/mL : A predictor of degree of upgrading to ≥8 among patients with biopsy gleason score 6. In: Investigative and clinical urology. 2017 ; Vol. 58, No. 2. pp. 90-97.
@article{e1fb14544caa4b709c820aa373686ffc,
title = "Prostate-specific antigen 10–20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy gleason score 6",
abstract = "Purpose: This study aimed to identify the predictors of upgrading and degree of upgrading among patients who have initial Gleason score (GS) 6 treated with robot-assisted radical prostatectomy (RARP). Materials and Methods: A retrospective review of the data of 359 men with an initial biopsy GS 6, localized prostate cancer who underwent RARP between July 2005 to June 2010 was performed. They were grouped into group 1 (nonupgrade) and group 2 (up-graded) based on their prostatectomy specimen GS. Logistic regression analysis of studied cases identified significant predictors of upgrading and the degree of upgrading after RARP. Results: The mean age and prostate-specific antigen (PSA) was 63±7.5 years, 8.9±8.77 ng/mL, respectively. Median follow-up was 59 months (interquartile range, 47–70 months). On multivariable analysis, age, PSA, PSA density and ≥2 cores positive were predictors of upgrading with (odds ratio [OR], 1.03; 95{\%} confidence interval [CI], 1.01–1.06; p=0.003; OR, 1.006; 95{\%} CI, 1.01–1.11; p=0.018; OR, 0.65; 95{\%} CI, 0.43–0.98, p=0.04), respectively. On subanalysis, only PSA level of 10–20 ng/mL is associated with upgrading into GS ≥8. They also had lower biochemical recurrence free survival, cancer specific survival, and overall survival (p≤0.001, p=0.003, and p=0.01, respectively). Conclusions: Gleason score 6 patients with PSA (10–20 ng/mL) have an increased risk of upgrading to pathologic GS (≥8), subsequently poorer oncological outcome thus require a stricter follow-up. These patients should be carefully counseled in making an optimal treatment decision.",
author = "Santok, {Glen Denmer R.} and Raheem, {Ali Abdel} and Kim, {Lawrence H.C.} and Kidon Chang and Lum, {Trenton G.H.} and Byungha Chung and Youngdeuk Choi and KoonHo Rha",
year = "2017",
month = "3",
day = "1",
doi = "10.4111/icu.2017.58.2.90",
language = "English",
volume = "58",
pages = "90--97",
journal = "Investigative and Clinical Urology",
issn = "2466-0493",
publisher = "Korean Urological Association",
number = "2",

}

Prostate-specific antigen 10–20 ng/mL : A predictor of degree of upgrading to ≥8 among patients with biopsy gleason score 6. / Santok, Glen Denmer R.; Raheem, Ali Abdel; Kim, Lawrence H.C.; Chang, Kidon; Lum, Trenton G.H.; Chung, Byungha; Choi, Youngdeuk; Rha, KoonHo.

In: Investigative and clinical urology, Vol. 58, No. 2, 01.03.2017, p. 90-97.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prostate-specific antigen 10–20 ng/mL

T2 - A predictor of degree of upgrading to ≥8 among patients with biopsy gleason score 6

AU - Santok, Glen Denmer R.

AU - Raheem, Ali Abdel

AU - Kim, Lawrence H.C.

AU - Chang, Kidon

AU - Lum, Trenton G.H.

AU - Chung, Byungha

AU - Choi, Youngdeuk

AU - Rha, KoonHo

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose: This study aimed to identify the predictors of upgrading and degree of upgrading among patients who have initial Gleason score (GS) 6 treated with robot-assisted radical prostatectomy (RARP). Materials and Methods: A retrospective review of the data of 359 men with an initial biopsy GS 6, localized prostate cancer who underwent RARP between July 2005 to June 2010 was performed. They were grouped into group 1 (nonupgrade) and group 2 (up-graded) based on their prostatectomy specimen GS. Logistic regression analysis of studied cases identified significant predictors of upgrading and the degree of upgrading after RARP. Results: The mean age and prostate-specific antigen (PSA) was 63±7.5 years, 8.9±8.77 ng/mL, respectively. Median follow-up was 59 months (interquartile range, 47–70 months). On multivariable analysis, age, PSA, PSA density and ≥2 cores positive were predictors of upgrading with (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.01–1.06; p=0.003; OR, 1.006; 95% CI, 1.01–1.11; p=0.018; OR, 0.65; 95% CI, 0.43–0.98, p=0.04), respectively. On subanalysis, only PSA level of 10–20 ng/mL is associated with upgrading into GS ≥8. They also had lower biochemical recurrence free survival, cancer specific survival, and overall survival (p≤0.001, p=0.003, and p=0.01, respectively). Conclusions: Gleason score 6 patients with PSA (10–20 ng/mL) have an increased risk of upgrading to pathologic GS (≥8), subsequently poorer oncological outcome thus require a stricter follow-up. These patients should be carefully counseled in making an optimal treatment decision.

AB - Purpose: This study aimed to identify the predictors of upgrading and degree of upgrading among patients who have initial Gleason score (GS) 6 treated with robot-assisted radical prostatectomy (RARP). Materials and Methods: A retrospective review of the data of 359 men with an initial biopsy GS 6, localized prostate cancer who underwent RARP between July 2005 to June 2010 was performed. They were grouped into group 1 (nonupgrade) and group 2 (up-graded) based on their prostatectomy specimen GS. Logistic regression analysis of studied cases identified significant predictors of upgrading and the degree of upgrading after RARP. Results: The mean age and prostate-specific antigen (PSA) was 63±7.5 years, 8.9±8.77 ng/mL, respectively. Median follow-up was 59 months (interquartile range, 47–70 months). On multivariable analysis, age, PSA, PSA density and ≥2 cores positive were predictors of upgrading with (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.01–1.06; p=0.003; OR, 1.006; 95% CI, 1.01–1.11; p=0.018; OR, 0.65; 95% CI, 0.43–0.98, p=0.04), respectively. On subanalysis, only PSA level of 10–20 ng/mL is associated with upgrading into GS ≥8. They also had lower biochemical recurrence free survival, cancer specific survival, and overall survival (p≤0.001, p=0.003, and p=0.01, respectively). Conclusions: Gleason score 6 patients with PSA (10–20 ng/mL) have an increased risk of upgrading to pathologic GS (≥8), subsequently poorer oncological outcome thus require a stricter follow-up. These patients should be carefully counseled in making an optimal treatment decision.

UR - http://www.scopus.com/inward/record.url?scp=85013683663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013683663&partnerID=8YFLogxK

U2 - 10.4111/icu.2017.58.2.90

DO - 10.4111/icu.2017.58.2.90

M3 - Article

C2 - 28261677

AN - SCOPUS:85013683663

VL - 58

SP - 90

EP - 97

JO - Investigative and Clinical Urology

JF - Investigative and Clinical Urology

SN - 2466-0493

IS - 2

ER -